J1740 HCPCS code: Injection, ibandronate sodium, 1 mg
J1740 is the HCPCS Level II code for injection, ibandronate sodium, 1 mg. In 2024 Medicare paid an average of $19.49 per service for J1740 across 4,506 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 3 per day on outpatient hospital claims. Medicare volume fell 35% from 2022 to 2024 (6,925 to 4,506 services). In 2024, about 328 clinicians billed Medicare for J1740 for 625 beneficiaries; New York, California, Florida accounted for 32% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2007-01-01 |
| Last action effective | 2024-01-01 |
Who bills J1740 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 328 |
| Medicare beneficiaries | 625 |
| States with claims | 17 |
| Share of services in top 3 states (New York, California, Florida) | 32% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J1740, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 6,925 | 923 | $33.10 | $24.49 |
| 2023 | 5,632 | 742 | $28.96 | $20.67 |
| 2024 | 4,506 | 625 | $27.33 | $19.49 |
States with the most J1740 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| New York | 541 | $21.55 |
| California | 361 | $19.59 |
| Florida | 351 | $20.29 |
| New Jersey | 335 | $19.41 |
| Minnesota | 282 | $20.18 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 3 | Prescribing Information |
| practitioner claims | 3 | Prescribing Information |
Medicare policy articles for this code
- A52421: Billing and Coding: Ibandronate Sodium (Wellpoint Federal (MAC - Part A, MAC - Part B))
- A56907: Billing and Coding: Bisphosphonate Drug Therapy (WPS Insurance Corporation (MAC - Part A, MAC - Part B))
Covered diagnoses (410 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| C79.51 | Secondary malignant neoplasm of bone | 2 |
| E83.52 | Hypercalcemia | 2 |
| M80.011A | Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture | 2 |
| M80.012A | Age-related osteoporosis with current pathological fracture, left shoulder, initial encounter for fracture | 2 |
| M80.021A | Age-related osteoporosis with current pathological fracture, right humerus, initial encounter for fracture | 2 |
| M80.022A | Age-related osteoporosis with current pathological fracture, left humerus, initial encounter for fracture | 2 |
| M80.031A | Age-related osteoporosis with current pathological fracture, right forearm, initial encounter for fracture | 2 |
| M80.032A | Age-related osteoporosis with current pathological fracture, left forearm, initial encounter for fracture | 2 |
| M80.041A | Age-related osteoporosis with current pathological fracture, right hand, initial encounter for fracture | 2 |
| M80.042A | Age-related osteoporosis with current pathological fracture, left hand, initial encounter for fracture | 2 |
Showing 10 of 410. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for J1740
- 2007-01-01: J1740 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J1740?
J1740 is the HCPCS Level II code for injection, ibandronate sodium, 1 mg. Short descriptor: "Ibandronate sodium injection".
How much does Medicare pay for J1740?
In 2024, the average Medicare payment was $19.49 per service (average allowed $27.33).
Does Medicare cover J1740?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for J1740?
Medicare policy articles that cite J1740 list 410 covered ICD-10-CM diagnosis codes across 2 articles. The most cited include C79.51 (Secondary malignant neoplasm of bone), E83.52 (Hypercalcemia), M80.011A (Age-related osteoporosis with current pathological fracture, right shoulder, initial encounter for fracture). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
How many units of J1740 can be billed per day?
3 on outpatient hospital claims; 3 on practitioner claims (NCCI medically unlikely edits).
Related J17 codes
- J1700 — Injection, hydrocortisone acetate, up to 25 mg
- J1710 — Injection, hydrocortisone sodium phosphate, up to 50 mg
- J1720 — Injection, hydrocortisone sodium succinate, up to 100 mg
- J1725 — Injection, hydroxyprogesterone caproate, 1 mg
- J1726 — Injection, hydroxyprogesterone caproate, (makena), 10 mg
- J1729 — Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg
- J1730 — Injection, diazoxide, up to 300 mg
- J1736 — Injection, meloxicam (delova), 1 mg
- J1737 — Injection, meloxicam (azurity), 1 mg
- J1738 — Injection, meloxicam, 1 mg
- J1741 — Injection, ibuprofen, 100 mg
- J1742 — Injection, ibutilide fumarate, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J1740
- Watch J1740 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J1740
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.